Table 1.
Current lower age of FDA-licensure for antiretroviral drugs obtained from package inserts
| Drug | Lower age for licensed prescribing |
|---|---|
| Nucleoside reverse transcriptase inhibitors | |
| Abacavir (Ziagen®) | 3 months |
| Didanosine (Videx®, Videx EC®) | 6 months, 6 years |
| Emtricitabine (Emtriva™) | 3 months |
| Lamivudine (Epivir®) | 3 months |
| Stavudine (Zerit®) | 6 months |
| Tenofovir disoproxil fumarate (Viread®) | 18 years |
| Zidovudine (Retrovir®) | 6 weeks (treatment dosing)
birth (prophylactic dosing) |
| Nonnucleoside reverse transcriptase inhibitors | |
| Efavirenz (Sustiva™) | 3 years |
| Etravirine (Intelence™) | 16 years |
| Nevirapine (Viramune®) | 15 days |
| Combination NRTI and/or NNRTI | |
| Abacavir + lamivudine (Epzicom®) | 16 years |
| Abacavir + lamivudine + zidovudine (Trizivir®) | Variable (>40 kg) |
| Tenfovir + emtricitabine (Truvada®) | 18 years |
| Tenfovir + emtricitabine + Efavirenz (Atripla®) | 18 years |
| Zidovudine + lamivudine (Combivir®) | 12 years |
| Protease inhibitors (PI) | |
| Atazanavir (Reyataz™) | 6 years |
| Darunavir (Prezista®) | 6 years |
| Fos-amprenavir (Lexiva™) | 2 years |
| Indinavir (Crixivan®) | 18 years |
| Lopinavir/ritonavir (Kaletra®) | 14 days |
| Nelfinavir (Viracept®) | 2 years |
| Ritonavir (Norvir®) | 2 years (treatment); variable as boosting agent with other PIs |
| Saquinavir (Invirase®) | 16 years |
| Tipranavir (Aptivus®) | 2 years |
| Entry and fusion inhibitors | |
| Enfuvirtide (Fuzeon™) | 6 years |
| Maraviroc (Selzentry®) | 16 years |
| Integrase inhibitor | |
| Raltegravir (Isentress®) | 16 years |